Can donated plasma shield newborns from chikungunya brain damage?

NCT ID NCT07190560

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de la Réunion Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving newborns plasma from people who recently recovered from chikungunya can prevent brain swelling or damage. The trial will include 60 newborns whose mothers were infected around the time of birth. Half will receive the plasma transfusion, and their outcomes will be compared to a group of 30 similar newborns who did not receive the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: plasma from recovered chikungunya patients
What this could lead to: If it works, this could provide a way to protect newborns from severe brain complications after chikungunya infection.
What could go wrong: This is a small, early-stage trial with only 60 participants, so results may not be conclusive. The treatment involves a plasma transfusion, which carries risks like allergic reactions or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain disorder chikungunya

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHIKUNGUNYA VIRUS INFECTION ENCEPHALOPATHY NEONATAL TRANSFUSION

Contacts and locations

Locations

CHU La Réunion
NOT_YET_RECRUITING

Saint-Pierre, 97410, France
Centre hospitalier de Mayotte
RECRUITING

Mamoudzou, Mayotte

More trials for these conditions

Other studies related to the condition(s) this trial covers.